$KPTI - On our trading list. The company announced that the FDA accepted the company's NDA filing for Xpovio in patients with relapsed or refractory diffuse large B-Cell lymphoma. A buy rating and $40 price target was reiterated by H.C. Wainwright.Karyopharm's Xpovio for DLBCL receives priority review, says H.C. WainwrightH.C. Wainwright analyst Edward White reiterated a Buy rating on Karyopharm and maintained a $40 price target after the company announced that the FDA accepted the company's NDA filing for Xpovio in patients with relapsed or refractory diffuse large B-Cell lymphoma after at least two prior multi-agent therapies and who are ineligible for stem cell transplantation and that its request for Priority Review was also granted. In addition, Karyopharm plans to submit an MAA to the EMA for Xpovio in r/r DLBCL in 2020, which could coincide with a multiple myeloma filing in Europe based on the Phase 3 BOSTON data for a more seamless submission process, White tells investors in a research note. The analyst expects Xpovio could receive approval for r/r DLBCL by the PDUFA date and launch shortly thereafter and estimates Xpovio sales of $3.6M in 2020 and $58.7M in 2026 for the DLBCL indication. $KPTI, Karyopharm Therapeutics Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page